MedTrace Logo

Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder

NCT00659347 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2008-12-05

No results posted yet for this study

Summary

The primary objectives of this placebo-controlled trial are to evaluate effectiveness and safety of DOV 21,947 at two oral dose levels.

Conditions

Interventions

DRUG

DOV 21, 947

Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks

DRUG

Placebo

Capsules,25 mg,BID,6weeks

Sponsors & Collaborators

  • DOV Pharmaceutical, Inc.

    lead INDUSTRY

Principal Investigators

  • Nuoyu Huang, MD/PhD · DOV Pharmaceutical, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States
  • Romania
  • Serbia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00659347 on ClinicalTrials.gov